Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Topotecan (NSC-609669) 是一种拓扑异构酶 I 抑制剂,通过抑制 DNA 拓扑异构酶起抗肿瘤作用,可用于治疗卵巢癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 417 | 现货 | ||
25 mg | ¥ 734 | 现货 | ||
100 mg | ¥ 1,820 | 现货 |
产品描述 | Topotecan (NSC-609669) is a Topoisomerase I inhibitor,and is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases. |
体外活性 | Topoisomerase I inhibitors, ?topotecan, inhibited growth and induced apoptosis of GSCs as well as glioma cells, which suggested that they might be the potential anticancer agents targeting gliomas to provide a novel therapeutic strategy[1]. |
体内活性 | Topotecan-水凝胶能够向玻璃体持续输送活性药物,具有优良的体内生物相容性以及在视网膜母细胞瘤细胞中明显的细胞毒作用,可能成为眼内视网膜母细胞瘤治疗的一个补充策略[2]。 |
细胞实验 | After isolated and identified the GSCs from glioma cells successfully, U251, U87, GSCs-U251 and GSCs-U87 cells were administrated with various concentrations of shikonin or topotecan at different time points to seek for the optimal administration concentration and time point.?The cell viability, cell cycle and apoptosis were detected using cell counting kit-8 and flow cytometer to observe the inhibitory effects on glioma cells and GSCs[1]. |
动物实验 | Hydrogel cytotoxicity was evaluated in retinoblastoma cells as a surrogate for efficacy and Topotecan vitreous pharmacokinetics and systemic as well as ocular toxicity were evaluated in rabbits. The pseudoplastic behavior of the hydrogels makes them suitable for intraocular administration. In vitro release profiles showed a sustained release of Topotecan from PCL-PEG-PCL up to 7days and drug loading did not affect the release pattern. Blank hydrogels did not affect retinoblastoma cell viability but 0.4% (w/w) Topotecan-loaded hydrogel was highly cytotoxic for at least 7days. After intravitreal injection, Topotecan vitreous concentrations were sustained above the pharmacologically active concentration. One month after injection, animals with blank or Topotecan-loaded hydrogels showed no systemic toxicity or retinal impairment on fundus examination, electroretinographic, and histopathological assessments[2]. |
别名 | NSC 609669, 拓扑替康, SKF 104864A |
分子量 | 421.45 |
分子式 | C23H23N3O5 |
CAS No. | 123948-87-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 84 mg/mL (199.31 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3728 mL | 11.8638 mL | 23.7276 mL | 59.319 mL |
5 mM | 0.4746 mL | 2.3728 mL | 4.7455 mL | 11.8638 mL | |
10 mM | 0.2373 mL | 1.1864 mL | 2.3728 mL | 5.9319 mL | |
20 mM | 0.1186 mL | 0.5932 mL | 1.1864 mL | 2.966 mL | |
50 mM | 0.0475 mL | 0.2373 mL | 0.4746 mL | 1.1864 mL | |
100 mM | 0.0237 mL | 0.1186 mL | 0.2373 mL | 0.5932 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Topotecan 123948-87-8 Autophagy DNA Damage/DNA Repair Topoisomerase orally active NSC-609669 NSC609669 NSC 609669 GSCs-U251 inhibit U87 Inhibitor U251 拓扑替康 SKF 104864A GSCs-U87 inhibitor